company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23979000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,23979000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3576000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3576000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20403000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,28520000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,143581000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,10195000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,182296000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-161893000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3378000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2599000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-779000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-162672000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-162672000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-162672000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-162672000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,155860000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,155860000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,156400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19064000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19064000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3267000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3267000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15797000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,32526000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,139331000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1107000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,172964000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-157167000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,15619000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1489000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-14130000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-171297000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-171297000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-171297000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-171297000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,172563000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.99
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,172563000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.99
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,173000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.99
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,24957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,24957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3712000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3712000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21245000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,36572000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,132132000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,774000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,169478000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-148233000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1927000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,595000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1332000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-149565000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-149565000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-149565000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-149565000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,178735000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.84
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,178735000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.84
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,178100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.84
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,33889000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,33889000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3647000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3647000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,30242000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,32574000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,135230000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,7200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,176961000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-146719000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10405000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,327000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1847000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-11925000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-158644000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-158644000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-158644000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-158644000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,173259000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.84
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,173259000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.84
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,173100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.84
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22429000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22429000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3367000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3367000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,19062000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,35552000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,143012000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,780000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,179344000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-160282000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3955000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,455000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1489000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4989000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-165271000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-165271000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-165271000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-165271000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,198935000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,198935000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,199100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,31622000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,31622000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3086000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3086000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,28536000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,40915000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,155082000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,2112000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,198109000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-169573000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3683000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,484000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-27234000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-30433000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-200006000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-200006000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-200006000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-200006000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,200397000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,200397000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,200000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23795000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,23795000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3228000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3228000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20567000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,48855000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,170434000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,866000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,220155000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-199588000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3951000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,493000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-5911000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-9369000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-208957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-208957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-208957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-208957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,200887000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,200887000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,200900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,65524000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,65524000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3049000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3049000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,62475000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,62478000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,168888000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-2257000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,229109000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-166634000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7686000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,523000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-6595000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-13758000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-180392000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-180392000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-180392000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-180392000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,200402000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.9
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,200402000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.9
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,200200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.9
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,73662000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,73662000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2666000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2666000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,70996000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,71523000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,158612000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,760000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,230895000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-159899000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12001000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1402000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-5598000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-16197000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-176096000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-176096000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-176096000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-176096000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,202329000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.87
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,202329000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.87
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,202400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.87
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,114424000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,114424000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,9306000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,9306000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,105118000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,96663000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,173604000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,741000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,271008000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-165890000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6962000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,202000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2220000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8980000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-174870000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,24448000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-199318000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-199318000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-25249000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-174069000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,204413000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.85
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,204413000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.85
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,204800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.85
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,659200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,659200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,38406000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,38406000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,620794000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,110654000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,189052000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,105800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-419000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,405087000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,215707000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7059000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,77000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-8115000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-15097000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,200610000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-27842000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,228452000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,228452000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,7342000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,221110000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,206002000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.06
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,219349000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.02
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,208600000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.06
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,563340000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,563340000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,30127000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,30127000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,533213000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,121881000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,186438000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,992000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,309311000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,223902000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-26022000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-39362000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,239000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-13101000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,210801000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,22660000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,188141000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,188141000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,29512000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,158629000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,204891000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.8
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,208807000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.84
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,211200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.8
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,438737000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,438737000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,39211000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,39211000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,399526000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,111146000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,196371000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,360000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,307877000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,91649000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3741000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3741000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,87908000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,32000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,87876000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,87876000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-3714000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,91590000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,208018000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.44
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,219264000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.43
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,208200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.44
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,418305000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,418305000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,114423000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,114423000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,303882000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,117514000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,196544000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,594000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,314652000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10770000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3635000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3635000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14405000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,20063000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-34468000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-34468000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,30463000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-64931000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,211344000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,211344000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,209500000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,336006000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,336006000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,38536000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,38536000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,297470000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,97684000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,200161000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,696000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,298541000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1071000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-4041000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4041000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5112000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,21355000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26467000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26467000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,31076000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-57543000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,213767000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.27
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,213767000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.27
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,213100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.27
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,333994000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,333994000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,87715000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,87715000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,246279000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,106337000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,172829000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,194000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,279360000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-33081000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-15040000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,11726000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3314000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-36395000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-41725000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,5330000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-83406000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-78076000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-1928000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-76148000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,211946000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.36
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,215262000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.35
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,214100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.36
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,328368000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,328368000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,42743000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,42743000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,285625000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,92879000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,218095000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,412900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,39000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,723913000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-438288000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3465000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1187000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4652000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-442940000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-130313000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-312627000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-312627000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-4611000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-308016000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,215421000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.43
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,215421000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.43
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,215400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.43
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,310750000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,310750000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,37931000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,37931000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,272819000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,106521000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,222455000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,776000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,329752000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-56933000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6551000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-27000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-6578000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-63511000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1799000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-61712000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-61712000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-4547000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-57165000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,222053000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.26
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,222053000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.26
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,219900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.26
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,221700000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,221700000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,27339000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,27339000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,194361000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,86427000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,219442000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,12048000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,317917000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-123556000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,95000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,4751000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,4656000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-118900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2555000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-121455000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-2677000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-124132000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-124132000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,230505000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.54
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,230505000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.54
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,229900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.54
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,351157000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,351157000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,22264000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,22264000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,328893000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,70361000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,222105000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,27658000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,320124000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,8769000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-10111000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-22926000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,3353000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-9462000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-693000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,7135000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7828000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-181251000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,242522000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,53443000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,9158000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,44285000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,224906000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.25
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,224906000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.25
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,224800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.25
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,118451000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,118451000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,15476000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,15476000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,102975000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,74212000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,238617000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,6188000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,319017000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-216042000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,15717000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,451000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-15266000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-231308000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,803000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-232111000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-232457000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-232457000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,232887000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,232887000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,232500000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,138421000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,138421000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,17300000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,17300000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,121121000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,77446000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,224487000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-270000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,301663000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-180542000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,15585000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,37731000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,22146000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-158396000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,693000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-159089000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-159382000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-159382000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,233808000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.68
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,233808000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.68
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,234400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.68
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,178987000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,178987000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,14184000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,14184000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,164803000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,75224000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,190939000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,40843000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,307006000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-142203000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,20384000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3990000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-24374000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-166577000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3419000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-169996000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-170060000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-170060000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,236137000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.72
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,236137000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.72
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,236200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.72
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,138509000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,138509000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,12307000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,12307000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,126202000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,85860000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,215599000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-3272000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,298187000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-171985000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,21307000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-5113000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-26420000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-198405000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,299000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-198704000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-198704000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-98000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-198606000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,239493000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,239493000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,239300000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,166076000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,166076000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,16860000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,16860000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,149216000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,94394000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,223858000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,2128000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,320380000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-171164000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,21111000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1414000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-19697000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-190861000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,30131000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-220992000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-220992000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-32144000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-188848000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,240757000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.78
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,240757000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.78
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,242100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.78
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,309816000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,309816000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,31960000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,31960000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,277856000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,99772000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,246284000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1826000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,347882000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-70026000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,21134000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1326000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-22460000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-92486000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1330000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-93816000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-93816000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,1333000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-95149000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,241969000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.39
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,241969000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.39
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,244000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.39
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,417935000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,417935000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,63385000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,63385000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,354550000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,96549000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,310181000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1524000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,408254000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-53704000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-63552000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-84206000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1690000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-22344000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-76048000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1379000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-74669000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-74669000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-938000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-73731000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,241312000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,241312000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,240800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,398080000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,398080000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,50649000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,50649000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,347431000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,105214000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,255860000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,687000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,361761000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14330000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,20698000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,4411000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-16287000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-30617000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,5485000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-36102000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-36102000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,5529000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-41631000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,243831000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,243831000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,244900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,431608000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,431608000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,45252000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,45252000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,386356000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,111652000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,271008000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,343000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,383003000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3353000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,20155000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1219000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-21374000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18021000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,18100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-36121000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-36151000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,28374000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-64525000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,244482000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.26
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,244482000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.26
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,248200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.26
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,413783000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,413783000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,54077000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,54077000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,359706000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,106055000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,272370000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,8000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,378433000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18727000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,20140000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-167000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-20307000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-39034000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,503000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-39537000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-39537000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-696000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-38841000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,244920000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,244920000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,242800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,458706000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,458706000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,60482000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,60482000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,398224000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,109908000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,248452000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,224000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,358584000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,39640000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-60993000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-81432000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1105000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-19334000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,20306000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-7423000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,27729000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,27759000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-5186000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,32945000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,244685000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.13
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,244685000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.13
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,243600000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.13
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,714718000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,714718000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,46988000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,46988000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,667730000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,113326000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,273563000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,9999000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,396888000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,270842000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,16765000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-544000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-17309000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,253533000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3985000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,249548000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,249548000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,1792000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,247756000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,246024000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.01
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,248700000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.99
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,245300000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.01
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,544135000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,544135000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,71205000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,71205000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,472930000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,127249000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,289451000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,3523000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,420223000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,52707000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,14664000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2537000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-17201000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,35506000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,4337000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,31169000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,31169000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,13173000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,17996000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,247521000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.07
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,251635000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.07
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,257100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.07
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,578165000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,578165000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,72874000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,72874000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,505291000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,120710000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,454947000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,255340000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,337000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,831334000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-326043000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,13574000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-77553000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-91127000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-417170000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-125903000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-291267000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-291267000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-188315000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-102952000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,250268000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.41
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,250268000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.41
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,251100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.41
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,651634000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,651634000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,84052000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,84052000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,567582000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,134794000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,306664000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,387000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,441845000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,125737000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,24295000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,11748000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-748000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-13295000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,112442000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,10257000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,102185000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,102185000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,1501000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,100684000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,248858000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.39
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,253225000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.39
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,248600000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.39
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,640799000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,640799000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,71613000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,71613000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,569186000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,129808000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,310553000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-76000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,440285000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,128901000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,16886000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5789000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,96838000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,85741000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,214642000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-12659000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,227301000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,227301000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,17038000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,210263000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,253231000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,258526000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.81
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,253300000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,752157000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,752157000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,104382000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,104382000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,647775000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,137303000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,337532000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,62000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,474897000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,172878000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,18155000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,8049000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,53819000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,43713000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,216591000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,10341000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,206250000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,206250000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-1110000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,207360000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,254135000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.82
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,258584000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.8
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,252900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.82
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1567046000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1567046000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,111255000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,111255000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1455791000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,137295000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,330510000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,782511000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-174000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1250142000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,205649000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,18686000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,10543000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-60995000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-69138000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,136511000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,8055000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,128456000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,128456000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-300000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,128746000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,254905000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.51
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,259788000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.5
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,252400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.51
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,87595000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,87595000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,122289000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,122289000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-34694000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,153210000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,437881000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-782511000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,29000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,4000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,-162416000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,127722000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,18744000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,13971000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-90452000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-95225000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,32497000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1492599000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1525096000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1525096000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-25421000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1550527000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,254292000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,6.08
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,259185000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,5.98
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,254500000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,6.08
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,858435000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,858435000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,95092000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,95092000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,763343000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,147045000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,339490000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,486535000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,276808000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,14868000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,15615000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,42610000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,43357000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,320165000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,51534000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,268631000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,268631000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,268631000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,255695000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.05
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,260175000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.03
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,255800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.05
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,941293000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,941293000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,135740000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,135740000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,805553000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,156502000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,379091000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,535593000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,269960000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,14837000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,18076000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,53939000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,57178000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,327138000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,59711000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,267427000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,267427000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,267427000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,256154000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,259822000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.03
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,257100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1899656000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1899656000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,131914000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,131914000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1767742000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,159674000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,555948000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,949828000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,2959000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1668409000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,99333000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,14548000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,17628000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-31747000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-28667000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,70666000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,13100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,57566000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,57518000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,57518000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,256946000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.22
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,260473000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.22
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,261400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.22
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,463437000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,463437000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,185012000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,185012000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,278425000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,195277000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,480011000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-949828000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,1500000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,-273040000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,551465000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,14249000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,12359000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,127375000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,125485000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,676950000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,93764000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,583186000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,583234000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,583234000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,256728000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.27
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,260673000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.23
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,256900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.27
